Dapagliflozin induces renal lipidomic remodeling and systemic metabolic improvement
Abstract Background Diabetic nephropathy (DN) is a leading cause of end-stage renal disease worldwide. Sodium-glucose cotransporter-2 inhibitors (SGLT2is), such as dapagliflozin, have demonstrated renoprotective effects in the treatment of DN. In addition to kidney protection, SGLT2is confer signifi...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMC
2026-04-01
|
| Цуврал: | Biology Direct |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1186/s13062-026-00800-9 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|